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Abstract  
Introduction: Molecular characterization of malaria parasites from different localities is important to improve understanding of acquisition of 
natural immunity to Plasmodium falciparum, to assist in identifying the most appropriate strategies for control and to evaluate the impact of control 
interventions. This study aimed to determine the genetic diversity and the multiplicity of infection in Plasmodium falciparum isolates from Pointe-
Noire, Republic of Congo. Methods: Plasmodium falciparum isolates were collected from 71 children with uncomplicated malaria; enrolled into the 
study for evaluating the therapeutic efficacy of artemether-lumefantrine combination. Both msp-1 and msp-2 genes were genotyped. 
Results: From 296 distinct fragments detected, 13 msp-1 and 27 msp-2 different alleles were identified. For msp-1, RO33 family was poorly 
polymorphic. The K1 family has shown the trend of predominance (41%), followed by Mad20 (35%). Comparatively to msp-2, 49.6% and 48.8% 
fragments belonged to 3D7 and FC27 respectively. Taking together msp-1 and msp-2 genes, the overall multiplicity of infection has been increased 
to 2.64 and 86% harbored more than one parasite genotype. Parasite density was not influenced by age as well as the multiplicity of infection 
which was not influenced neither by age nor by parasite density. Conclusion: Genetic diversity of Plasmodium falciparum in isolates from patients 
with uncomplicated malaria in Pointe-Noire is high and consisted mainly of multiple clones. The overall multiplicity of infection has been largely 
increased when considering msp-1 and msp-2 genes together. With the changes in malaria epidemiology, the use of both msp-1 and msp-2 genes 
in the characterization of Plasmodium falciparum infection is recommended. 
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Introduction 
 
Malaria, a disease mainly caused by Plasmodium falciparum, 
remains a public health concern. Although massive interventions 
deployed in sub-Saharan Africa have reduced the global malaria 
morbidity and mortality at 212 million and 429,000 deaths 
respectively in 2015, some sub-Saharan Africa region had provided 
partial data regarding the impact of certain interventions [1]. In the 
Republic of Congo, malaria is still the leading cause of attendance in 
health facilities. The latest estimations from the National Malaria 
Control Program indicate that clinical malaria account for 47.9% of 
all outpatient consultations in public hospitals, 64.8% of hospital 
admissions and 18.4% of deaths [2]. The high levels of resistance 
of Plasmodium falciparum to chloroquine as well as the inefficacy of 
sulphadoxine-pyrimethamine and amodiaquine either singly or in 
combination for the treatment of uncomplicated malaria have been 
well documented [3-6]. Thus, the Republic of Congo has changed 
its anti-malarial drug policy for treating uncomplicated malaria to 
artemisinin-combination therapies (ACTs) in 2006 [7]. Studies 
aiming to evaluate the efficacy of these combinations have been 
conducted mainly in Brazzaville [8-10]. Only one was done in 
Owando, located in the north part of the Republic of Congo [11]. 
Although the efficacy of artesunate-amodiaquine and artemether-
lumefantrine is still high as reported in these previous studies, it is 
important to extend the efficacy assessment as well as to evaluate 
the impact of these combinations on the malaria parasite population 
dynamic and the multiplicity of Plasmodium falciparum infection 
(MOI) in other localities, nine years after the implementation of 
artesunate-amodiaquine and artemether-lumefantrine in Republic of 
Congo. 
  
Genetic diversity of circulating Plasmodium falciparum strain, the 
occurrence of variant forms of the parasite in different geographic 
areas and variation of MOI after recombination between genetically 
distinct gametocytes, constitute the major obstacles to the design of 
a malaria vaccine [12, 13]. Consequently, these two parameters 
allow characterization of malaria parasites in human populations and 
improve understanding of acquisition of natural immunity 
to Plasmodium falciparum and would assist in identifying the most 
appropriate strategies for control and also to evaluate the impact of 
control interventions [14, 15]. The merozoite surface protein-
1 (msp-1) and merozoite surface protein-2 (msp-2) are asexual 
blood stage antigens that are considered prime candidates for the 
development of malaria vaccine, and also suitable markers used 
extensively to identify genetically distinct Plasmodium 
falciparum parasite sub-populations in many malaria endemic 
countries as well as to distinguish recrudescence to re-infection in 
anti-malarial drug trials and efficacy [16-18]. It has been proposed 
that with the change of malaria epidemiology, both msp-1 and msp-
2 allele frequency and genetic diversity should be monitored 
regularly to ensure the reliability of the PCR (polymerase chain 
reaction)-adjusted treatment outcome [18]. To our knowledge, in 
the Republic of Congo, after the introduction of artemisinin 
combination therapy (ACTs), the most epidemiological studies 
on Plasmodium falciparum genetic diversity have been conducted in 
Brazzaville [15, 19]. However, only one has been done in one health 
facility in the city of Pointe-Noire, the second largest city in the 
country, using msp-2 gene as marker [20]. Conversely, there is no 
information on msp-1 diversity in Pointe-Noire. During the study 
aiming the efficacy assessment of artemether-lumefantrine 
combination in Pointe-Noire in 2015, we proposed to determine the 
genetic diversity of Plasmodium falciparum in the recruited 







The present study was conducted at the “Centre de Santé Intégré 
de Mbota” located in the eastern part of the city of Pointe-Noire, the 
economic capital of the Republic of Congo, separated by 510km 
from Brazzaville. Two rainy seasons are observed each year with the 
main one during the months of February to May, and a short one 
from October to December. Malaria endemicity is high with 
perennial transmission and peaks during the rainy season, which 
normally runs from October to May [3] and malaria infection is 
primarily due to Plasmodium falciparum. 
  
Study population and blood samples collection 
  
Infected blood with Plasmodium falciparum was collected from 
children under 13 years old enrolled into the study (study 
ACTRN12615001110572) for evaluating the therapeutic efficacy of 
artemether-lumefantrine combination from September to November 
2015. Diagnostic of Plasmodium falciparum was confirmed by light 
microscopy on thick blood smears. Malaria parasites were quantified 
against 200 leucocytes. Parasite density was calculated for each 
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patient assuming an average of 8,000 leucocytes per µL of blood 
using the proposed method of the WHO [21]. Before treatment, 
blood sample from each patient was blotted on the Watman filter 
paper (3MM CHR), dried and transferred to the “Laboratoire 
National de Santé Publique” in Brazzaville, where isolation of DNA 
and genotyping were performed. The clinical study on artemether-
lumefantrine efficacy was approved by the institutional “Comité 
d’Ethique de la Recherche en Sciences de la Santé” (N° 
038/DGRST/CERSSA in June 2015) of the Congolese Ministry of 
Research and the Ministry of Health and Population of Republic of 
Congo. 
  
Extraction of parasite DNA 
  
Genomic DNA was extracted from samples collected on the Watman 
filter paper by QIAamp DNA mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instruction. Extracted DNA was 
stored at -20°C until use. 
  
Plasmodium falciparum msp-1 and msp-2 genotyping 
  
Samples genotyping of Plasmodium falciparum was performed using 
the nested polymerase chain reactions (PCRs) technique. The 
merozoite surface protein-1 (msp-1) and merozoite surface protein-
2 (msp-2) genes in their highly polymorphic loci, namely msp-
1 block 2 and msp-2 central region were used as markers for this 
genotyping as described previously [16, 17, 22, 23]. PCR 
amplification was performed following a 2-step amplification 
procedure, in which the initial amplifications were followed by 
individual nested PCR reactions using specific primers for K1, Mad20 
and RO33 allelic families for msp-1, and FC27 and 3D7 allelic 
families for msp-2 (Table 1). Allelic specific and DNA free negative 
controls were included in each step of the reaction. Five microliters 
of each of the PCR products were loaded on 2% agarose gel 
(PeqLab, Erlangen, Germany), stained with ethidium bromide, 
separated by electrophoresis and visualized under ultraviolet trans-
illumination. Individual alleles were identified by fragment length 
and by the corresponding allele-specific primers used and the size of 
the PCR products were estimated using 100bp DNA ladder marker 
(Invitrogen, Karlsruhe, Germany). The size polymorphism in each 
allelic family (Table 1), assuming that one band represented one 
amplified PCR fragment derived from a single copy of Plasmodium 
falciparum msp-1 and msp-2 genes. Alleles in each family were 
considered the same fragment size was within 20 bp interval [17]. 
  
Data and statistical analysis 
  
The frequency of msp-1 and msp-2 allele was calculated as the 
proportion of allele found for the allelic family out of the alleles 
detected in isolates. The mean expected heterozygosity (He) value 
for each allelic family of msp-1 and msp-2 genes was calculated as 
described by Mohd Abd Razak et al. [24]. The detection of one msp-
1 and msp-2 allele was considered as one parasite genotype. The 
multiplicity of infection was defined as the minimum number 
of Plasmodium falciparum genotypes per infected subject and 
estimated by dividing the number of amplified PCR fragments 
reflecting the parasite genotypes by the number of positive samples. 
Chi-square test was applied to compare proportions. Spearman’s 
rank correlation coefficients were calculated to assess association 
between multiplicity of infection (MOI) and geometric mean parasite 






Characteristics of patients and parasite density 
  
A total of 71 patients with malaria and microscopically 
confirmed Plasmodium falciparum only were enrolled in the study, 
with 34 (47.9%) and 37 (52.1%) being males and females 
respectively. Twenty-six and 45 were children aged between 1 to 4 
years old and 5 to 12 years old respectively. The geometric mean 
parasite density was 36,699.6 parasites/µl of blood with the range 
of 1,435-349,700 parasites/µl (Table 2). 
  
Plasmodium falciparum genotyping of msp-1 and msp-2 
  
All 71 samples were analyzed for polymorphisms on msp-
1 and msp-2 genes. The efficiency of msp-1 and msp-2 genes 
amplification reactions with family-specific primers were 100% and 
97.2% respectively. With a total of 296 distinct fragments detected, 
13 msp-1 and 27 msp-2 different alleles were identified. The msp-
1 gene analysis showed 70, 60, 41 fragments belonged to K1 (41% 
of overall detected msp-1 alleles), Mad20 (35%) and R033 (24%) 
families respectively. Eight K1 type alleles (He value of 0.82), 4 
Mad20 (He value of 0.68) type alleles and only 1 RO33 type allele 
(150 pb) were identified, with no statistical significant predominance 
of any specific family (Figure 1). The msp-2 gene yielded 13 3D7 
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type alleles (He value of 0.92) and 14 FC27 type alleles (He value of 
0.93), with no statistical significant predominance of any specific 
family (Figure 2). Out of 123 fragments identified, 62 fragments 
belonged to 3D7 (49.6% of overall detected msp-2 alleles) and 61 
belonged to FC27 (48.8%). Two genotypes (1.6%) could not be 
assigned to any specific family. 
  
Plasmodium falciparum multiplicity of infection, parasite 
densities in relation to age 
  
When considering msp-1 and msp-2 genes separately, the MOI was 
2.40 and 1.74 respectively, while 55 (77.46%) and 34 (47.88%) of 
isolates contained multiclonal infection at least with 2 clones 
respectively. Taking together msp-1 and msp-2 genes, the overall 
MOI was 2.64 and 61 (86%) isolates harbored more than one 
parasite genotype. No statistical significant difference was observed 
in the MOI between patients with less than 5 years old (2.44) and 
those with the age between 5 and 12 years old (2.40) with the p-
value = 0.972. The combinations of msp-1 and msp-2 different 
parasite genotypes were not associated with the parasite density 
(Table 3), as well as the MOI was not associated with parasite 
density (Table 4). Moreover, the age was not associated 
significantly with the parasite density (p-value = 0.381). Taking 
together, no statistical significant difference was observed in the 





The genetic diversity may be an important element for 
implementing malaria control strategies in the country, as 
elimination may influence genetic diversity [25]. In the Republic of 
Congo, most of the studies on the Plasmodium falciparum genetic 
diversity using merozoite surface protein genes which are 
considered like robust and suitable markers [22, 25, 26] have been 
conducted in Brazzaville, the political capital [5, 15, 17, 19, 27]. 
With the expanding access to ACT and current changes in malaria 
epidemiology, it has been encouraged to monitor regularly 
the Plasmodium falciparum msp-1 and msp-2 allele frequency-
genetic diversity [18], despite some debate around their usefulness 
as markers of population structure [14, 28]. To our knowledge, this 
present study represents the first investigation of genetic diversity 
of Plasmodium falciparum populations to employ both msp-
1 and msp-2 gene markers, 9 years after the implementation of 
ACTs for the treatment of uncomplicated Plasmodium 
falciparum malaria in Pointe-Noire. 
  
Allelic specific PCR typing of msp-1 and msp-2 genes showed a high 
genetic diversity in the Plasmodium falciparum population in the 
analyzed isolates. The degree of polymorphism found in the present 
study is also consistent with the previous findings in the same area 
using microsatellites markers [29]. The msp-2 gene has showed a 
high diversity as previously reported in Pointe-Noire [20]. 
Although msp-1 gene was amplified in all isolates, genetic diversity 
still low compared to msp-2 gene as previously described in the 
country [17]. With regard to msp-1, the presence of Mad20, K1 and 
R033 allelic families in the 71 isolates was noticed. RO33 family was 
poorly polymorphic with only one allele as reported in previous 
studies in Brazzaville and other countries such as Senegal, Iran, 
Nigeria and Brazil [13, 17, 30-32] in contrast to findings in Gabon 
and Côte d’Ivoire [33]. Although the K1 family has shown the trend 
of predominance (41%), followed by Mad20 (35%), the difference 
in prevalence between these free families was not statistically 
significant. Comparatively to msp-2, no predominance to any allelic 
family was found. Taking together msp-1 and msp-2, our findings 
are in contrast to those reported in previous studies in Brazzaville 
and other countries such as Gabon, Benin, Ghana, and Ethiopia 
where K1 for msp-1 and 3D7 for msp-2 were predominantly found 
in isolates from uncomplicated malaria [17, 25, 33-36]. 
  
The trend observed in the prevalence of K1 and 3D7 families in the 
current study may be related to the limited sample size. Repeated 
studies including a large sample size and different sites including 
symptomatic and asymptomatic Plasmodium falciparum infection in 
Pointe-Noire are needed to better characterize the allelic 
polymorphism of Plasmodium falciparum in this city. Understanding 
the diversity of Plasmodium falciparum has implications for vaccine 
since the major obstacles to the design of an efficient malaria 
vaccine is the large genetic diversity of vaccine targets allowing 
parasites with mutated genes to escape from the host’s immune 
response [16]. Thus, different genetic profiles of malaria parasites 
even within or between countries should be taken into account in 
the prospect of vaccine development against Plasmodium 
falciparum for improving vaccine design. 
  
The presence of more than one parasite genotype was detected in 
86% of isolates from Pointe-Noire, with the MOI values for msp-
1 and msp-2 genes of 2.40 and 1.74 respectively. The overall MOI 
value of 2.64 was found, when taking together msp-1 and msp-
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2 genes and this was higher than values obtained from Brazzaville, 
even before or after the introduction of ACTs [5, 17, 19, 20]. 
Despite the lack of entomological data from Pointe-Noire and 
Brazzaville, the number of clones coinfecting a single host can be 
used as an indicator of the level of malaria transmission or the level 
of host acquired immunity [12, 28, 33, 37]. Therefore, the 
discrepancies on the MOI may suggest the different level of malaria 
transmission between these two cities, with Brazzaville being more 
urbanized. Studies conducted in Mali and Malawi have confirmed 
lowest levels of MOI and proportions of polygenomic infections in 
areas exhibiting low malaria transmission, namely in the urban sites 
and highest levels where malaria transmission is almost perennial 
[38, 39]. Multiple parasite types in a single human host have been 
suggested to lead to cross fertilization, meiotic recombination and 
generation of new strains during the developmental stage in the 
mosquito [12, 13, 40]. This supports the fact that both MOI and 
polymorphism are high in Pointe-Noire. Since no data are available 
on the MOI in Pointe-Noire before the introduction of ACT, it seems 
difficult to evaluate the impact of this measure on the MOI in this 
city. The MOI was influenced neither by age nor by parasite density 
in this population in contrast with the previous findings in 
Brazzaville, Tanzania and Sudan [17, 26, 41, 42], but concordant 
with those in Ethiopia and Mali [25, 39]. Therefore, regardless of 
the parasite densities, and the fact that the samples collection has 
been done during the peak malaria transmission, the prevalence of 





Genetic diversity of Plasmodium falciparum in isolates from patients 
with uncomplicated malaria in Pointe-Noire, Republic of Congo is 
high and consisted mainly of multiple clones. By considering msp-
1 and msp-2 genes together, the overall multiplicity of infection has 
been largely increased. Thus, with the changes in malaria 
epidemiology, this study supports the use of both msp-1 and msp-
2 genes in the characterization of Plasmodium falciparum infection, 
when the MOI is considered like one of the major parameters to be 
evaluated for malaria control interventions. 
 
What is known about this topic 
 Malaria is still the leading cause of attendance in health 
facilities in many sub-Saharan countries; 
 Plasmodium falciparum genetic diversity would assist in 
identifying the most appropriate strategies for control and 
also to evaluate the impact of control interventions as well 
as changes in malaria epidemiology; 
 Little data available regarding the Plasmodium falciparum 
genetic diversity and the MOI using both msp-1 and msp-
2 as molecular markers, particularly in Pointe-Noire, the 
Republic of Congo. 
What this study adds 
 Genetic diversity of Plamosdium falciparum is high and 
consisted mainly of multiple clones in Pointe-Noire; 
 Increase MOI when msp-1 and msp-2 are used together 
as molecular markers; 
 The epidemiological trend of malaria seems to be different 
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Table 1: Oligonucleotides sequences used for single and nested PCR of Plasmodium 
falciparum msp-1and msp-2 genes [16], and range of fragment size of the alleles 
msp-1 gene msp-2 gene 


























Range of fragment size of the alleles 
msp-1 allelic families 
Mad20 alleles:180bp to 300bp 
RO33 alleles : 150bp to 280bp 
K1 alleles:130bp to300bp 
msp-2 allelic families 
  
FC27 alleles: 260bp to540bp 
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Table 2: Characteristics of patients with uncomplicated Plasmodium 
falciparum malaria in Pointe- Noire, Republic of Congo 
Characteristics of patients Values 
Gender (Male/Female) 34/37 
Mean age (years) 5.98 (1-12) 
 Group of age < 5 years (%) 26 (36.6) 
 Group of age ≥ 5 years (%) 45 (63.4) 
Mean parasite density (parasites/µl) 36,699.6 (1,435-349,700) 
Multiplicity of infection 2. 64 (1-6) 





Table 3: Distribution of msp-1 and msp-2 detected allelic families 
according to the parasite densities 
Mean parasite densities 
msp-1 msp-2 
  FC27 3D7 FC27 + 3D7 
K1 146840 118222 4466 
Mad20 53295 24219 4060 
RO33 113982 135877 0 
K1+Mad20 36063 57954 119478 
K1+RO33 157537 12077 79840 
Mad20+RO33 47697 26370 5140 




Table 4: Profile of multiple infections 







1 10 39,981 
2 22 32,092 
3 27 39,057 
4 8 38,964 
5 3 18,879 
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Figure 3: Relation between mean geometric density and multiplicity of infection with age 
 
